Meloxicam/rizatriptan
| Combination of | |
|---|---|
| Meloxicam | Nonsteroidal anti-inflammatory drug |
| Rizatriptan | serotonin (5-HT) 1B/1D receptor agonist (triptan) |
| Clinical data | |
| Trade names | Symbravo |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a625033 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
Meloxicam/rizatriptan, sold under the brand name Symbravo, is a fixed-dose combination medication used for the treatment of migraine. It is a combination of meloxicam, a nonsteroidal anti-inflammatory medication; and rizatriptan (as rizatriptan benzoate), a serotonin (5-HT) 1B/1D receptor agonist (triptan). It is taken by mouth.
Meloxicam/rizatriptan was approved for medical use in the United States in January 2025.